Ohio State University Comprehensive Cancer Center

Axi-Cel Therapy Shows Reduced Toxicities in Large B-Cell Lymphoma Treatment

5 months ago

• Axicabtagene ciloleucel (axi-cel) therapy demonstrates a significant decrease in the severity and duration of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). • The reduced severity of CRS and ICANS leads to improved patient outcomes, including a decreased need for intensive care and shorter hospital stays, enhancing the risk-benefit profile of axi-cel. • Prophylactic and preemptive strategies, such as early use of steroids and tocilizumab, contribute to the improved safety profile of axi-cel in treating relapsed or refractory large B-cell lymphoma. • Overall survival (OS) was not different across study periods, suggesting that reduced toxicities do not compromise the effectiveness of axi-cel, though longer follow-up is needed to assess long-term quality of life.

CAR T-cell Therapy Shows Promise in Treating B-cell Lymphoma

3 years ago

Recent studies highlight the effectiveness of CAR T-cell therapy in treating aggressive B-cell lymphoma, with significant response rates and manageable adverse events. Real-world data and long-term follow-ups support its use, despite challenges like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.